Management of Severe Alcoholism with Liver Disease

Medication Guidance

The European Association for the Study of Liver Diseases explicitly states that naltrexone is contraindicated in alcoholic liver disease 1
Naltrexone should NOT be used in patients with severe liver disease due to documented hepatocellular injury risk and formal contraindication in hepatic insufficiency per product labeling 2, 3, 4
Acamprosate is the preferred pharmacotherapy for alcohol dependence in patients with liver disease because it is not metabolized by the liver and carries no hepatotoxicity risk 2, 3, 1
The American Association for the Study of Liver Diseases recommends acamprosate as the preferred agent specifically due to its lack of hepatotoxicity 1

Determine if hepatic insufficiency or cirrhosis is present using non-invasive methods (FibroScan, FibroTest, or FibroMeter Alcohol) 2, 3
Check AST, bilirubin, and platelet levels 2, 3
Use short-acting benzodiazepines (oxazepam or lorazepam) for alcohol withdrawal syndrome in cirrhotic patients 2, 3, 5
Prescribe thiamine prophylactically to prevent Wernicke's encephalopathy 2, 3

Start acamprosate 666 mg (two 333 mg tablets) three times daily for patients ≥60 kg 6
Reduce dose by one-third for patients <60 kg 6
Adjust to 333 mg three times daily for moderate renal impairment (CrCl 30-50 mL/min) 1, 6
Continue treatment for 3-6 months minimum, up to 12 months 6
Acamprosate must be combined with comprehensive psychosocial treatment and counseling for optimal efficacy 4, 6

Never use naltrexone in patients with severe liver disease or hepatic insufficiency 2, 3, 1
Avoid disulfiram in severe liver disease due to hepatotoxicity risk 1, 5
Baclofen may be considered as an alternative in patients with cirrhosis, with one randomized trial showing benefit in achieving and maintaining abstinence 4

Acamprosate is designed to maintain abstinence, not induce it, and starting it too early reduces efficacy because its mechanism works best for maintaining rather than achieving abstinence in patients with a history of alcohol use 7, 8
The drug has not been shown to have significant impact on alcoholics who have not been detoxified or become abstinent, with clinical trials demonstrating efficacy specifically enrolling patients who were already detoxified 7, 8

Naltrexone is contraindicated in patients with severe liver disease due to documented hepatocellular injury risk, making acamprosate a safer option for patients with alcoholic liver disease 7
Acamprosate has moderate-quality evidence for both maintaining abstinence and acceptability up to 12 months, with low dropout rates, and is the only intervention with sufficient evidence of benefit for maintaining alcohol abstinence in primary care settings 9, 10, 11

The American College of Physicians and other guideline societies recommend acamprosate as a first-line treatment for alcohol use disorder, with evidence suggesting its efficacy in maintaining abstinence and reducing relapse rates 9, 10, 11